Craft
ImmunoGen

ImmunoGen

Patents Issued

1.4 K

FY, 2020

Revenue

$69.9 M

FY, 2021

Market Capitalization

$1.2 B

2022-11-21

ImmunoGen Summary

Company summary

Overview
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, that is in a clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in a clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm.
Type
Public
Status
Active
Founded
1981
HQ
Waltham, MA, US | view all locations
Website
https://www.immunogen.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Mark Enyedy

    Mark Enyedy, President, Chief Executive Officer, Director

  • Audrey Bergan

    Audrey Bergan, Senior Vice President and Chief Human Resources Officer

  • Susan Altschuller

    Susan Altschuller, Senior Vice President and Chief Financial Officer

  • Stacy Coen

    Stacy Coen, Senior Vice President, Chief Business Officer

Operating MetricsView all

Patents Issued

1.4K
7.7%

FY, 2020

Patent Applications

600
7.7%

FY, 2020

LocationsView all

1 location detected

  • Waltham, MA HQ

    United States

    830 Winter St

ImmunoGen Financials

Summary financials

Revenue (Q2, 2022)
$14.2M
Net income (Q2, 2022)
($62.0M)
Cash (Q3, 2022)
$309.5M
EBIT (Q2, 2022)
($61.1M)
Enterprise value
$877.7M

Footer menu